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Azita Rasti1, Sharda Suman1, Raúl Torres-Ruiz7,8, Antonio Sarno9,10,11, Elisée Wiita1, Evert
J. Homan1, Stella Karsten 1, Karthick Marimuthu1, Maurice Michel1, Tobias Koolmeister1,
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ABSTRACT
Altered oncogene expression in cancer cells causes
loss of redox homeostasis resulting in oxidative
DNA damage, e.g. 8-oxoguanine (8-oxoG), repaired
by base excision repair (BER). PARP1 coordinates
BER and relies on the upstream 8-oxoguanine-DNA
glycosylase (OGG1) to recognise and excise 8-oxoG.
Here we hypothesize that OGG1 may represent an
attractive target to exploit reactive oxygen species
(ROS) elevation in cancer. Although OGG1 depletion
is well tolerated in non-transformed cells, we report
here that OGG1 depletion obstructs A3 T-cell lym-
phoblastic acute leukemia growth in vitro and in vivo,
validating OGG1 as a potential anti-cancer target. In
line with this hypothesis, we show that OGG1 in-
hibitors (OGG1i) target a wide range of cancer cells,
with a favourable therapeutic index compared to
non-transformed cells. Mechanistically, OGG1i and
shRNA depletion cause S-phase DNA damage, repli-
cation stress and proliferation arrest or cell death,
*To whom correspondence should be addressed. Tel: +44 1142159677. Email: t.helleday@sheffield.ac.uk
Correspondence may also be addressed to Torkild Visnes. Tel: +47 92217744. Email: torkild.visnes@sintef.no.
†The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.
C© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which






















































































2 Nucleic Acids Research, 2020
representing a novel mechanistic approach to tar-
get cancer. This study adds OGG1 to the list of BER
factors, e.g. PARP1, as potential targets for cancer
treatment.
INTRODUCTION
Transformed cancer cells are characterized by increased lev-
els of DNA damage (1,2) as a result of lost redox home-
ostasis, oncogene-induced replication stress and impaired
DNA repair pathways (3,4). As a consequence, cancers may
become addicted to efficient repair and hence, targeting
the DNA damage response and repair (DDR) pathways
is an established anti-cancer strategy (5). The base exci-
sion repair (BER) pathway, involving PARP1 and glycosy-
lases such as 8-oxoguanine-DNA glycosylase 1 (OGG1), is
repairing the vast majority of DNA lesions. We and oth-
ers previously demonstrated that PARP inhibitors are ef-
fective in treatment of homologous recombination defec-
tive (HRD) cancers (6,7) and currently four different PARP
inhibitors are approved for treating several HRD cancers.
By trapping PARP on DNA (8), clinically used PARP in-
hibitors interfere with replication forks (9,10), alternative
end-joining (11–13) and other pathways (14,15). Whereas
PARP1-inhibitors also blocks BER (16), targeting the BER
pathway as such has not been validated as an anti-cancer
target. Most of the focus in the DDR inhibitor (DDRi)
field has been targeting proteins involved in signallingDNA
double-strand breaks (DSBs) or replication stress (RS),
such as ATR, ATM, CHK1 and WEE1 kinases currently
evaluated in clinical trials (17).
It is well established that expression of oncogenes such
asMYC and RAS lead to the generation of reactive oxygen
species (ROS) and oxidative DNA damage (18–21). Thus,
high levels of oxidized bases have been found in the genome
of cancer cells (22,23), which excrete oxidized bases and nu-
cleotides into serum and urine serving as robust biomarkers
for cancer (22,23), also reviewed in (24,25). The most com-
mon result of ROS DNA damage is the oxidation of gua-
nine to 8-dihydro-7,8-oxoguanosine (8-oxodG) in DNA,
repaired by OGG1. Whereas the presence of 8-oxodG in
DNA is miscoding, the signature C→A transversion mu-
tation is surprisingly rare in human malignancies (26). This
indicates that high-ROS cancers may rely on efficient path-
ways to repair ROS-induced DNA damage.
Surprisingly,Ogg1−/− mice are alive and grow old, albeit
having increased incidence of lung cancer at the age of 18
months (27). Interestingly, OGG1 overexpression protects
cells against Ras-induced senescence (28) and high OGG1
expression is correlated with lower genomic instability in a
panel of adenocarcinoma cell lines (29).Moreover, the tran-
scriptional activity of genes (PCNA, KRAS,MYC, VEGF)
and transcription factors (NF-B) involved in cell prolifer-
ation, and initiation or progression of cancer can be modu-
lated upon introduction and processing of 8-oxodG within
promoters and 5′ untranslated regions via BER (30–34), al-
together suggesting a role forOGG1 in cancer development.
While targeting the BER pathway, with for instance
PARP inhibitors, is a validated strategy to treat cancer,
other BER targeting strategies have received surprisingly lit-
tle attention (35,36). Here, we validate OGG1 as an anti-
cancer target, which confirms targeting oxidative DNA re-
pair as a concept for treatment of cancer. Furthermore, this
validates that BER inhibitors, other than PARP inhibitors,
are effective as anti-cancer treatments.
MATERIALS AND METHODS
Cell culture
Adherent and suspension cell lines were cultured in RPMI
(61870-010 Thermo Fisher Scientific), McCoy’s (36600-021
Thermo Fisher Scientific) or DMEM (10566-016 Thermo
Fisher Scientific) media depending on the cell line. The
media was supplemented with 10% fetal bovine serum
(10500064, Thermo Fisher Scientific) and 100 U/ml Peni-
cillin Streptomycin (15140122, Thermo Fisher Scientific)
and the cells were cultured at 37◦C and 5% carbon dioxide.
TheBJ-Tert andBJ-Ras cell lines were provided byW.Hahn
(Dana-Farber Cancer Institute), MEF Ogg1−/- cells from
M. Bignami (Istituto Superiore di Sanità, Rome, Italy),
HCT116 and HCT116+Chr3 human colon carcinoma cells
were obtained from Dr. Bert Vogelstein (2001, Johns Hop-
kins, Baltimore, MD, USA), Hec59 and Hec59+Chr2 from
(37), LCL#1 and LCL#2 from J. Benitez (Spanish National
Cancer Research Centre,Madrid, Spain), and the rest of the
cell lines were sourced from commercial suppliers American
Type Culture Collection (ATCC) or the German Collec-
tion ofMicroorganisms and Cell Cultures GmbH (DMSZ).
All cultures were passaged a maximum of 25 times after
thawing from stock vials and checked for mycoplasma con-
tamination using MycoAlert™ Mycoplasma Detection Kit
(Lonza) every other month.
RNA interference
200 000 immortalized BJ-Tert and 100 000 transformed
BJ-Ras-SV40 cells were seeded in six-well plates, incu-
bated overnight and transfected with siRNA duplexes us-
ing Interferin (# 409–50, Polyplus Transfection) accord-
ing to instructions. After 48 h, 3000 BJ-Tert cells and
1000 BJ-Ras cells per well were seeded in 96-well plates
and reverse transfected with the same siRNA sequence
according to instructions. The final concentrations of
siRNA duplexes were 10 and 2.7 nM for the forward
and reverse transfections, respectively, and the siRNA se-
quences were siOGG1#1: 5′-GGAUCAAGTAUGGACA
CUGAC-3′, siOGG1#2: 5′-GGACAAUCUUUCCGGU
GGA-3′. AllStars negative control siRNA (SI03650318, Qi-
agen) was used as transfection control.
Stable transfections with doxycycline-inducible small
hairpin RNA was performed with the plasmid pRSITEP-
U6Tet-(sh)-EF1-TetRep-P2A-Puro-P2A-RFP670 (38) and
transduced into A3 and H460 cell lines as described (38).
The non-targeting shRNA sequence was identical to the
one described in (38), and the hairpins recognizing OGG1
hybridized to the following sequences in the OGG1 open
reading frame shOGG1#1: 5′-GGAGTGGTGTACTAGC
GGATC-3′, shOGG1#2: 5′-GTGTGCGACTGCTGCG























































































Nucleic Acids Research, 2020 3
Viability
Cells were seeded in 96- or 384-well plates and incu-
bated for 3 days for combination experiments or 5 days
for single-drug exposure experiments. Resazurin (R7017,
SigmaAldrich) was added to a final concentration of
0.01 mg/ml resazurin and fluorescence was measured at
ex530/em590 after incubation for 2, 4 or 6 h. Curves were
fitted using XLfit software (IDBS) or Prism 8.0 (Graphpad
Software), and EC50 values were determined.
Colony formation assays
BJ-Tert and BJ-Ras cell lines were transfected with siRNA
for 48 h as described above, trypsinized, counted and seeded
in 6-well plates at 300 cells per well and incubated until
colony size surpassed 50 cells, followed by medium removal
and addition of 4% (w/v) methylene blue in methanol.
Following extensive washes in tap water and air drying,
colonies with >50 cells were counted.
H460 cells harboring knockdown constructs were treated
with 500 ng/ml doxycycline for 48 h, trypsinized, counted
and seeded in 6-cm diameter petri dishes for 9 days in
the presence of an equivalent concentration doxycycline.
Colonies exceeding 50 cells were fixed, stained and enumer-
ated as above.
The indicated concentrations TH5487 were spotted in 6-
well plates using a Tecan D300e digital dispenser. 200–500
cells/well H460, ACHN,Ogg1−/− mouse embryonic fibrob-
lasts andMRC5 cells were then seeded at 200–500 cells/well
and incubated for 7–11 days. Colonies exceeding 50 cells
were fixed, stained and enumerated as above.
250HEK293T orHEK293T (KO) cells were counted and
seeded in 6-well plates for 8 days in the presence or absence
of TH5487 at indicated concentrations. Colonies were di-
rectly scanned after removing media and drying colonies.
Area ofHEK293T orHEK293T(KO) colonies was digitally
colour contrasted and then analysed using ImageJ.
PBMC isolation
Peripheral blood mononuclear Cells (PBMC) were iso-
lated from peripheral whole blood from controls using
Histopaque®-1077 (Sigma-Aldrich, San Luis, MO, USA)
following the manufacturer’s instructions. Briefly, periph-
eral blood was collected in heparin and diluted with
equal amount of PBS. Next, blood was centrifuged with
Histopaque®-1077 at 400 × g for 30 min at room tempera-
ture and the PBMC layer was recovered. All steps were pro-
cessed within 4 h after blood extraction.
The samples were obtained from healthy donors who
signed an appropriate informed consent and the proposal
was approved by the ethics committee at the Fuenlabrada
University Hospital, Madrid, Spain. The study was per-
formed in accordance with the principles of the Declaration
of Helsinki.
CD34+ isolation and culture
Isolation of total CD34+ cells was performed from um-
bilical cord blood samples (CB) from healthy donors dis-
tributed from Centro de Transfusión de la Comunidad de
Madrid. All samples were collected under written con-
sent and institutional review board agreement. CD34+
cells was obtained from mononuclear cells were sepa-
rated by fractionation in Ficoll-hypaque according to man-
ufacturer’s recommendations (GE Healthcare). Purified
CD34+ cells were obtained using a MACS CD34 Micro-
Bead kit (Miltenyi Biotec) and were cultured in StemSpan
SFM II (StemCell Technologies) containing 100 U/ml
penicillin/streptomycin (Gibco) and a cytokine cocktail of
SCF (100 ng/ml), TPO (100 ng/ml), Flt3 ligand (100 ng/ml,
Peprotech. Cells were cultured at 37◦C, 5%CO2 and 5%O2.
Activation of T-cells using Phytohemagglutinin-L (PHA-L)
or dynabeads
PMBCs and CD34- fraction (CB) were cultured in the
presence of PHA-L (Sigma-Aldrich, ref: 11249738001)
or Dynabeads® Human T-Activator CD3/CD28 (Ther-
mofisher scientific, ref: 11131D) for the activation and ex-
pansion of human T cells according to the manufacturer’s
instructions.
CD3 flow cytometry assay
The experiment was performed on blood cells from 4 differ-
ent healthy individuals, with three replicates each. Human
peripheral bloodmononuclear cells were isolated from fresh
buffy coats obtained from healthy donors via the Karolin-
ska Hospital, Stockholm, Sweden. For separation, Ficoll-
Paque PLUS density medium (17144003, GE Healthcare)
and SepMate separation tubes (85450, StemCell) were used,
according to manufacturer’s instructions. Briefly, buffy coat
diluted 1:1 with PBS and layered on 15 ml of Ficoll-Paque
PLUS in the SepMate tubes was spun down for 10 min at
12 000 × g. The upper layer of the tube content was then
poured into new falcon tubes and washed twice with PBS.
Cells were seeded out in round bottom 96-well plates
(83.3925.500, Sarstedt) in RPMI Medium 1640 containing
GlutaMAX™ (61870-010, ThermoFisher) supplemented
with 10% human AB+ male heat inactivated clotted
whole blood serum (H5667, Sigma-Aldrich) and 100 U/ml
penicillin/streptomycin (15140122, Gibco). Non-activated
cells were seeded at a concentration of 1 × 106 cells/ml. For
CD3/CD28 activation, Dynabeads™ Human T-Activator
CD3/CD28 (11131D, ThermoFisher) weremixedwith 0.8 1
× 106 cells/ml at a concentration of 0.75 beads per cell. Only
viable cells were counted, using a TC20™ automated cell
counter (Bio-Rad) and Trypan blue (1450021, Bio-Rad).
The total volume of medium per well was 200 l. DMSO
and TH5487 were added directly into the wells, at a con-
centration of 0.25% and 25 M, respectively. After 3 days
of activation and treatment, 50 l fresh complete medium
containing DMSO or TH5487 was added to the wells for an
additional 3 days.
After 6 days of culture, 90 l cells were moved to
a Nunc™ 96-Well Polystyrene Conical Bottom MicroW-
ell™ Plate (249935, ThermoFisher), containing 10 l of
cold CellWASH (349524, BD) per well, supplemented
with 5 l Precision Count Beads™ (424902, BioLegend)
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Mouse Anti-Human CD3 (563423, BD), PE Mouse Anti-
Human CD8 (561950, BD), APC Mouse Anti-Human
CD71 (334108, Nordic Biosite) as an additional activation
marker and APC-H7 Mouse Anti-Human CD4 (560158,
BD). The plate was incubated at 4◦C for 30 min and then
washed with cold CellWASH. The samples were then re-
suspended in 100 l of Annexin V Binding buffer (422201,
Nordic Biosite), containing 0.5 l FITC-conjugated An-
nexin V (556420, BD) and 1:500 SYTOX™ Blue Dead Cell
Stain (S34857, ThermoFisher) and incubated at RT for 15
min, protected from light. The cells were then moved to
flow cytometry tubes containing 100 l additional Cell-
WASH, incubated on ice for at least 10 min and then
run with a 3-laser Navios flow cytometer from Beckman
Coulter.
10 000 events from anFSC-SSC gate set on the typical liv-
ing lymphocyte population were collected and the data was
compensated and analyzed using FlowJo 10.5.3. The CD3
positive cells were gated for and plotted in a Sytox Blue-
Annexin V graph, where the double-negative cells were con-
sidered viable. The number of CD3 positive, viable events
was quantified and then divided by the number of Precision
Count Beads™ collected per tube. This cell-per-bead num-
ber was further divided by the mean of the DMSO viable
CD3+ cell-per-bead population, in order to generate a rela-
tive concentration of living CD3 positive cells in relation to
the DMSO samples. For gating, Fluorescence-Minus-One
(FMO) samples were used as technical controls. For com-
pensation, single-stains and unstained samples were run
fresh for every new experiment. Data was further analyzed
and plotted using Microsoft Excel and GraphPad Prism
8.
Lentiviral generation of cell lines
The Photinus pyralis luciferase gene from the vector
pGL4.32 (Promega) was cloned into pENTR1A no CCDB
plasmid (w48-1, AddGene 17398), and shuttled into the
pLenti-PGK-hygro DEST (w530-1, AddGene 19066) plas-
mid, packaged into lentiviruses as described (38) and trans-
duced into A3 cells containing shRNA constructs as de-
scribed above and selected with 300 g/ml hygromycin or
20 g/ml blastidicin for 10 days.
Immunoblotting
Cells were washed in cold PBS and lysed in RIPA
buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1% NP-40, 0.5% sodium deoxycholate and 0.1%
SDS supplemented with complete protease inhibitor cock-
tail (04693116001, Roche), freeze-thawed once, incubated
20min on ice followed by sonication at 80% amplitude, 0.7
cycle and 10 cycles in a UP100H (Hielscher Ultrasonics)
and clarification by centrifugation. Proteins were separated
and blotted with 4–12% polyacrylamide gels and the Trans-
Blot Turbo transfer system, respectively (BioRad). The fol-
lowing primary antibodies were used: rabbit anti-OGG1
(ab124741, Abcam) 1:2500, mouse anti-Actin (ab6276, Ab-
cam) 1:10 000, goat anti-vinculin 1:1000, rabbit anti-histone
3 (ab1791, Abcam) 1:5000, mouse anti-H2AX(p-Ser139)
(05-636, Millipore) 1:2000).
8-oxodG detection in genomic DNA
8-oxodG detection in genomic DNA through LC–MS/MS
(39) and single-cell electrophoresis (40) were performed as
described.
Immunofluorescence
A3 cells were seeded in a 96-well plate 24 h prior to start
of the experiment. Cells were then treated with 10 M
TH5487, for 24, 48 and 72 h, respectively or with 2 mM hy-
droxyurea for 1 h. Final DMSO concentration was 0.2%.
After the treatment, cells were transferred to an imaging
plate (black Falcon 96-well plate) pre-coated with 0.1% poly
L-lysine (Sigma). Cells were allowed to attach for 15 min-
utes and were then fixed with 4% paraformaldehyde. The
plate was washed with 0.05% Tween 20 in PBS, cells were
permeabilized with 0.5% Triton-X100 in PBS and blocked
with 2% bovine serum albumin in PBS. Incubation with
primary antibody (mouse anti-H2AX, Millipore, prod-
uct no. 05-636, dilution 1:1000) in 2% BSA/PBS was per-
formed at 4◦C overnight. After washing with 0.05% Tween
20 in PBS, cells were incubated with secondary antibody
(Alexa Fluor anti-mouse 647, Thermo Scientific, dilution
1:400) together with DAPI staining at room temperature
for 1 h. Plate was washed thoroughly with 0.05% Tween
20 in PBS and imaged with ImageXpress (Molecular De-
vices, CA, USA). Image analysis was completed with Cell
profiler software. Mean intensities of H2AX signal in sin-
gle nuclei were averaged and compared between the treat-
ment and control. Statistical analysis was performed using
GraphPad 7.0c software. Data from three independent ex-
periments were pooled and analyzed for statistical signifi-
cance by one-way analysis of variance.
RNA-sequencing in A3 shNT cells
To extract bulk RNA from cells, the pellets were resus-
pended in 500 l of TRI Reagent. After 5 min, 100 l of
chloroform was added and the tubes were shaken by hand
for one minute. After 15 min incubation, the samples were
centrifuged at 12 000 × g for 15 min at 4◦C. 300 l of the
aqueous phase were then mixed thoroughly with 300 l of
Isopropanol, 30 l of 3M Sodium Acetate and 1 l of Pel-
let Paint (Merck 69049) and incubated over night at−20◦C.
The following day, the samples were centrifuged at 20 000
× g g for 30 min and the pellets washed twice with 600 l
of 70% ethanol. After drying, the pellets were resuspended
in 15 l of Elution Buffer and the concentration of RNA
was measured using the Qubit RNAHigh Sensitivity Assay
(Thermo Fischer Q32852) according to the manufacturer’s
instructions.
After diluting the samples, 2 ng of RNA were used as in-
put for the Smart-seq2 RNA-sequencing protocol (41) and
50 bp single ends were sequenced on an Illumina HiSeq
3000 sequencer. Reads were mapped to the ENSEMBL hu-
man transcriptome GRCh37 using Tophat 2.1.1 to generate
the read count matrix.
Transcriptome data analysis in A3 cells
Differential expression analysis was performed with DE-
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hancedVolcano package (v.1.4.0). For functional analysis
Gene Sets were retrieved with the msigdbr package (v7.1.1).
For Gene Set Enrichment Analysis only genes with a mean
expression>5 normalized counts as determined byDESeq2
were taken into account. GSEA was performed using the
gsea package (v.1.12.0) that implements the algorithms de-
scribed by Subramanian et al. (43). Heatmaps were gen-
erated using the ComplexHeatmap package (v.2.2.0) (44).
Mapping of log2 fold normalized counts onto the DNA
Replication KEGG (Kyoto Encyclopedia of Genes and
Genomes) pathway was done using the pathview package
(v.1.26.0) (45). All analyses were performed in R v.3.6.0.
RNA extraction, quantification and real time PCR analysis
RNA was extracted from cultured cells using TRIzol®
Reagent (Thermo Fisher Scientific). RNA quantity and
quality were assessed by NanoDrop® (ND-1000 V3.7.1;
Thermo Fisher Scientific). The High-Capacity cDNA Re-
verse Transcription Kit (Applied Biosystems) was utilized
for cDNA synthesis following the manufacturer’s instruc-
tions. Two microliters of cDNA at a final concentration
of 10 ng/l were mixed with GoTaq® qPCR MasterMix
1× (Promega) and 1 M cDNA primers of each pair of
primers (F/R) in a final volume reaction of 10 l. Primers
used are listed in Supplementary Table S2. The amplifica-
tion conditions consisted of an initial step at 95◦C for 10
min, followed by 40 cycles of 10 s at 95◦C and 1 min at
60◦C. Each qPCR was performed in duplicates or tripli-
cates including no-template controls in an Abi QuantStu-
dio 1 Flex Real-Time PCR System (Applied Biosystems).
Relative transcript levels for each replication gene, was cal-
culated using the 2Ct method for qPCR analysis after
normalization with the housekeeping gene beta-actin (B-
actin-F 5′-CCTGGCACCCAGCACAAT- 3′; B-actin-R 5′
- GGGCCGGACTCGTCATACT-3′).
Oxidative DNA damage within MCM4 gene promoter
We adapted the procedure described by O’Callaghan et al.
(46) to measure oxidative DNA damage at theMCM4 gene
promoter region. This is a qPCR method based on differ-
ences in PCR kinetics between DNA template digested by
FPG and undigested DNA. We have modified the origi-
nal protocol to incorporate another purified human OGG1
to quantify the accumulation of base lesions specific for
OGG1, 8-oxoguanine. Conditions used for incubation were
200 ng of gDNA together with 2.4 M of hOGG1 dur-
ing 4 h. The quantitative real-time amplification of genomic
DNA was performed as described by O’Callaghan et al.
(46). Specific primers were used at a final concentration
of 100 nM (promoterMCM4-F: 5′-GCTGTGATTGGTGA
GGCCC -3′; promoterMCM4-R: 5′-CAAACCGCGAGA
CCCAGAG-3′) . Amplification cycling conditions were 10
min at 95◦C, followed by 40 cycles of 95◦C for 15 s and 60◦C
for 1 min. CT method was run in an ABI quant studio 1
and all samples were loaded and analyzed in triplicate.
EdU flow cytometry analysis
At the indicated time points, compound/dox treated cells
were incubated in medium containing 10 M 5-ethynyl-2′-
deoxyuridine (EdU) (Thermo Fisher, A10044) for 20 min.
Next, cells were fixed in cold 70% ethanol overnight. The
azide alkyne Huisgen cycloaddition (‘Click reaction’) was
carried out according to the Click-iT EdU Imaging Man-
ual (Thermo Fisher) using various fluorescent dyes: Alexa
Fluor® 488 azide (ThermoFisher, A10266), Alexa Fluor®
647 azide (Thermo Fisher, A10277), or TAMRA azide
(Thermo Fisher, T10182), depending on assay conditions.
Samples were incubated with Alexa Fluor® 488 Mouse
anti-H2AX (pS139) (BD Biosciences, 560445) overnight at
4◦Cand finally stainedwithDAPI solution [10g/mlDAPI
(Sigma, D9542), 0.1 mg/ml RNase A (Thermo Fisher,
EN0531), 1% BSA in PBS] for 20 min at room temperature.
Measurements were done using a Navios Flow Cytome-
ter (Beckman Coulter). Data was analyzed using Kaluza®
Flow Analysis Software (Beckman Coulter).
Annexin V-staining
The annexin V staining experiment was performed using
BD Pharmingen FITCAnnexin VApoptosis Detection Kit
I (cat.no 556547) according to the protocol given in the kit.
Cells were washed with ice-cold PBS and then washed with
1X Annexin buffer diluted in ice-cold PBS. To the washed
pellet of cells, PI and FITC Annexin V dye was added and
incubated at room temperature in dark for 15 mins. After
the incubation, 400 l of annexin buffer was added and
run in Navios flow cytometer (Beckman Coulter) to detect
the apoptosis with blue laser(488 nm, filter 525/40 nm) and
dead cells with blue laser(488 nm, filter 620/30 nm). Kaluza
Flow Analysis (Beckman Coulter) was used for data analy-
sis.
DNA fibre assay
A3 Cells were exposed to either 0.1% DMSO or 10 M
TH5487 for the indicated times, pulse-labeled with 25
M 5-chloro-2′-deoxyuridine (CldU) for 30 min, washed
with medium and pulse-labeled with 250 M 5-iodo-2′-
deoxyuridine (IdU) for 30 min. Alternatively, control or
OGG1 shRNA expression was induced with 1 g/ml doxy-
cyline for 48 h or 96 h before pulse labelling. CldU was
detected by incubating acid-treated fiber spreads in Ibidi
-Slide VI 0.4 (Ibidi, 80606) with rat anti-BrdU mono-
clonal antibody (AbD Serotec; cat# MCA2060), whereas
IdU was detected using mouse anti-BrdUmonoclonal anti-
body (BD Biosciences; cat# 347580) for 1 h at 37◦C. Slides
were fixed with 4% paraformaldehyde and incubated with
goat anti-rat Alexa Fluor 555 or goat anti-mouse Alexa
Fluor 488 for 1.5–2 hours. Fibers were examined using a
Zeiss (Jena, Germany) LSM780 confocal laser scanningmi-
croscope with a 63× oil immersion objective. The lengths
of red (AF 555) or green (AF 488) labeled patches were
measured using the ImageJ software (National Institutes of
Health; http://rsbweb.nih.gov/ij/) and arbitrary length val-
ues were converted into micrometers.
Mouse xenograft experiment
Animal experiments were conducted as per the European
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animal ethical committee Stockholm 2010/63 (N8914).
Upon arrival to animal facility, animals were acclimatized
in the animal house for a week with ad lib food and wa-
ter, with a 12 h light cycle and the temperature and humid-
ity set according to laboratory animal guidelines and reg-
ulations. For the xenograft experiment involving inducible
shRNA, 1 × 107 non-targeting luciferase transfected A3
cells in 50% matrigel in PBS were injected into flank re-
gion of BALB/c nude mice. Later, mice from non-targeting
and shRNA groups were randomly divided into two groups
containing eight mice per group. One group from both non-
targeting and OGG1-targeting shRNA was given 1 mg/ml
doxycycline in drinking water from day 15 till last sur-
vival of mice (when tumor size was about to reached 1000
mm3). For the experiment involving native A3 cells, 8 ×
106 luciferase-transfected cells in 50%matrigel were injected
subcutaneously into NOD-SCIDmice. Treatment was initi-
ated 14 days after inoculation when tumour volume reached
approximately 100 mm3. TH5487 was formulated in a vehi-
cle solution of 5% DMSO, 10% tween-80, 10% Cremophor
and 75% water, and the indicated doses were administered
by oral gavage twice daily on weekdays for 6 weeks or un-
til tumor size reached 1000 mm3. Tumor volume was mea-
sured using calipers (length × 0.52 × width × width) and
bioluminescence images were taken using an IVIS spectrum
in vivo imaging system (Perkin-Elmer) after intraperitoneal
injection of D-luciferin (150 mg/kg in PBS). Following ter-
mination, tumors were ground in liquid nitrogen and re-
suspended in tris-buffered saline with complete protease
inhibitors (Roche), homogenized and subjected to the in-
dicated temperatures (47). Following lysis by three freeze-
thaw cycles, samples were centrifuged at 20 000 × g for 30
min, and OGG1 in the supernatant was detected by im-
munoblotting. Survival plots were drawn using Graphpad
Prism software.
Biochemical assay
OGG1 activity was assessed in vitro as previously described
(39).
Synthetic chemistry experimental section
All reagents and solvents were purchased from Sigma-
Aldrich, Combi-Blocks, Thermo Fischer Scientific, or
VWR and were used without purification. The compound
7-bromo-3-(4-piperidyl)-1H-benzimidazol-2-one;2,2,2-
trifluoroacetic acid was synthesized as described (39).
Unless otherwise stated, reactions were performed without
care to exclude air or moisture. Analytical thin-layer
chromatography was performed on silica gel 60 F-254
plates (E. Merck) and visualized under a UV lamp. Flash
column chromatography was performed in a Biotage®
SP4 MPLC system using Merck silica gel 60 Å (40–63
m mesh). 1H and 13C NMR spectra were recorded on a
Bruker DRX-400 MHz spectrometer. Chemical shifts are
expressed in parts per million (ppm) and referenced to the
residual solvent peak. Analytical LC–MS were performed
on an Agilent MSD mass spectrometer connected to an
Agilent 1100 system with: Method ST1090A3: Column
ACE 3 C8 (50 × 3.0 mm); H2O (+ 0.1% TFA) and MeCN
were used as mobile phases at a flow rate of 1 ml/min, with
a gradient from 10–90% in 3 min; or Method B0597 × 3:
Column Xterra MSC18 (50 × 3.0 mm); H2O (containing
10 mMNH4HCO3; pH 10) andMeCNwere used as mobile
phases at a flow rate of 1 ml/min, with a gradient of 5–97%
in 3 min. For LC–MS, detection was made by UV (254 or
214 nm) and MS (ESI+). Preparative LC was performed
on a Gilson system using Waters C18 OBD 5 m column
(30 × 75 mm) with water buffer (50 mM NH4HCO3 at pH
10) and acetonitrile as mobile phases using a flow rate of
45 ml/min. All final compounds were assessed to be >95%
pure by LC–MS analysis.




Step 1: A mixture of 7-bromo-3-(4-piperidyl)-1H-
benzimidazol-2-one;2,2,2-trifluoroacetic acid (1200 mg,
3.0 mmol), diisopropylethylamine (0.52 ml, 3.0 mmol),
and 3,4-dichlorophenylisocyanate (560 mg, 3.0 mmol) in
DCM (20 ml) was stirred at 20◦C for 16 h. The product
percipitated and was collected by filtration and washed
with DCM, water, and then DCM again. The solid was
dried at 40◦C under vacuum. LCMS [M+H]+ 483.
Step 2: A mixture of 4-(4-bromo-2-oxo-3H-
benzimidazol-1-yl)-N-(3,4-dichlorophenyl)piperidine-
1-carboxamide (73 mg, 0.15 mmol), potassium carbonate
(2M, 0.38 ml), [6-(hydroxymethyl)-3-pyridyl]boronic acid
(69 mg, 0.45 mmol), and Pd(PPh3)4 (8.7 mg, 0.0075 mmol)
was stirred under nitrogen atmosphere in dioxane at 95◦C
for 16 h. The mixture was thereafter concentrated and
purified by preparative LC, the product was isolated as the
TFA salt.
LCMS [M+H]+ 512. 1H NMR (400 MHz, DMSO-d6) 
ppm 11.22 (s, 1 H), 8.90 (s, 1 H), 8.79 (d, J = 1.6 Hz, 1 H),
8.30 (dd, J = 8.2, 1.9 Hz, 1 H), 7.89 (t, J = 1.3 Hz, 1 H),
7.81 (d, J = 8.2 Hz, 1 H), 7.49 (d, J = 1.6 Hz, 2 H), 7.36 (d,
J= 7.9 Hz, 1 H), 7.16 (t, J= 7.6 Hz, 1 H), 7.11 (dd, J= 7.9,
0.9 Hz, 1 H), 4.78 (s, 2 H), 4.47 (ddt, J = 16.3, 8.1, 3.9, 3.9
Hz, 1 H), 4.31 (d, J = 13.6 Hz, 2 H), 2.99 (t, J = 12.3 Hz, 2
H), 2.26 - 2.39 (m, 2 H), 1.73 - 1.81 (m, 2 H).
4-(4-Bromo-2-oxo-3H-benzimidazol-1-yl)-N-(4-iodo-3-
methyl-phenyl)piperidine-1-carboxamide (TH6943).
A mixture of 4-iodo-3-methyl-aniline (23 mg, 0.10
mmol), diisopropylethylamine (0.035 ml, 0.20 mmol),
and trichloromethyl carbonochloridate (0.0060 ml, 0.050
mmol) was stirred in DCM (2.0 ml) at 20◦C for 5 min. Then
the mixture was added to a vial charged with 7-bromo-3-
(4-piperidyl)-1H-benzimidazol-2-one 2,2,2-trifluoroacetic
acid (41 mg, 0.10 mmol), diisopropylethylamine (0.017 ml,
0.10 mmol) and DCM (2.0 ml). The resulting mixture was
stirred at 20◦C for 3 h. The solids were then filtered off and
washed with DCM, water, and then DCM again. The solid
was dried at 40◦C under vacuum, no further purification
was done.
LCMS [M+H]+ 555. 1H NMR (400 MHz, DMSO-d6) 
ppm 11.31 (br. s., 1 H), 8.64 (s, 1 H), 7.65 (d, J = 8.8 Hz, 1
H), 7.51 (d, J = 2.5 Hz, 1 H), 7.26 (br. d, J = 8.1 Hz, 1 H),
7.13–7.19 (m, 3 H), 6.96 (t, J= 8.1 Hz, 1 H), 4.35 - 4.45 (m,
1 H), 4.24 - 4.33 (m, 2 H), 2.89–2.99 (m, 2 H), 2.32 (s, 3 H),
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X-ray crystallography
A synthetic gene encoding hOGG1 [11–327] was expressed
as a cleavable N-terminally His-tagged protein in E. coli
BL21(DE3) T1R pRARE2 at 18◦C and purified using His-
Trap HP (GE Healthcare) followed by gel filtration us-
ing HiLoad 16/60 Superdex 200 (GE Healthcare) after tag
cleavage (Thrombin, GEHealthcare). Protein was stored in
20 mM MES at pH 6.0, 200 mM NaCl, 10% glycerol, 0.5
mM TCEP, at 20 mg/ml and stored at −80◦C.
Samples for co-crystallization were prepared by pre-
incubation of hOGG1 (18 mg/ml) with 2–4 mM of the lig-
ands (from a stock solution of 100 mM in DMSO). Crys-
tals of the hOGG1:TH5487 complex were obtained from
a hanging-drop vapor diffusion setup against 0.12 M Alco-
hols, 0.1MBuffer System 2 pH 7.5 and 48% v/v Precipitant
Mix 4 (Morpheus screen (48),Molecular Dimensions, UK).
A drop of 2 l of sample was mixed with equal amount of
reservoir and incubated at 16◦C. Crystals grew within 24
hours and were frozen in liquid nitrogen for data collec-
tion. Diffraction data (Supplementary Table S3) were col-
lected at station I04 of the Diamond Light Source (Didcot,
UK). A complete dataset was collected from a single crys-
tal at 100 K. Raw data images were processed and scaled
with xia2 (49), DIALS (50), and Aimless (51) using the
CCP4 suite 7.0 (52). Molecular replacement was performed
with the coordinates of human OGG1 (PDB code 1EBM),
to determine initial phases for structure solution in Phaser
(53). The working models were refined using Refmac5 (54)
and manually adjusted with Coot (55) Validation was per-
formed with Molprobity (56). Figures were drawn with Py-
MOL (Schrödinger, LLC, New York).
The atomic coordinates and structure factors (codes
6RLW) have been deposited in the ProteinData Bank (http:
//wwpdb.org).
Statistical analysis
Statistical analyses were performed with Prism 8.0 (Graph-
Pad Software). Statistical significance Figures 1A, B, D, E,
3D, E, F, 4D, E, G, H, J, K, 5A, C, D, E, F, I, K, 6D, E, F
and supplementary Figures S5A, B, S6A, S7A, B was deter-
mined using unpaired, two-sided t-tests (*P < 0.05, **P <
0.01, ***P < 0.001 and ****P < 0.0001) Statistical signif-
icance for Figure 3C and Supplementary Figure S4H was
determined using Paired t-test (****P < 0.0001). Statisti-
cal significance for Supplementary Figures S1B, S1C, S4E
and S4F was determined using Mann–Whitney unpaired
test for nonparametric distribution (*P< 0.05, **P< 0.01,
***P < 0.001 and ****P < 0.0001). Normality of the dis-
tribution for each data set was tested using Kolmogorov–
Smirnov test.
RESULTS
Validation of OGG1 as an anti-cancer target
While PARP inhibitors effectively block BER (16), target-
ing the BER pathway as such has not been validated as
an anti-cancer target since PARP inhibition also has impli-
cations on replication forks (9,10), alternative end-joining
(11–13) and other pathways (14). Since expression of the
frequently mutated RAS oncogenes leads to the generation
of ROS and oxidative DNA damage (19,20), we wanted to
determine if OGG1, which initiates the BER process by rec-
ognizing and excising 8-oxodG, is important for the survival
of transformed cells. To test this, we used siRNA to down-
regulate OGG1 in the well characterized isogenic hTERT-
immortalized BJ fibroblasts transformed or not with SV40
largeT antigen andHRASG12V (57). Five days after trans-
fection, we could observe a marked decrease in viability of
transformed cells, but little effect in non-transformed cells
(Figure 1A). Moreover, OGG1 knockdown decreased the
colony-forming ability of BJ-Ras, but not BJ-Tert cells, indi-
cating that OGG1 protected cells against oncogene-induced
stress (Figure 1B and C).
To further investigate if OGG1 depletion inhibited
growth in human transformed and cancer cell lines we
tested the colony forming ability in previously validated
OGG1 CRISPR-Cas9 depleted epithelial kidney embry-
onic cells (HEK293T(KO)) (39). Whereas the number of
colonies was similar in HEK293T (KO) cells compared to
the parental HEK293T OGG1 proficient cells, the colony
area generated by theHEK293T (KO) cells was significantly
smaller (Supplementary Figure S1A, S1B and S1C). In hu-
man cancer cell lines, depletion ofOGG1 in H460 lung can-
cer cells stably transfected with doxycycline-inducible small
hairpin RNA (shRNA) constructs targetingOGG1 reduced
clonogenic ability (Figure 1D and F). A3 T-cell acute lym-
phoblastic leukemia cells transduced with the same con-
structs divided normally for 48 h after addition of doxycy-
cline followed by slower proliferation and a loss of viability
thereafter (Figure 1E and F).
We then stably expressed luciferase in the same A3 in-
ducible cell line, which was injected subcutaneously into
Balb/C nude mice. Doxycycline was added to the drink-
ing water when tumor volume had reached 200 mm3. This
caused a regression in tumor size in xenografts harboring
OGG1-targeting shRNA, whilst tumors with non-targeting
shRNA were unaffected (Figure 2A and B, Supplemen-
tary Figure S2). After seven weeks, only mice injected with
OGG1-knockdown cells remained alive (Figure 2C). These
data show that OGG1 protects cancer cells from oncogenic
stress in vivo and validate OGG1 as anti-cancer target.
OGG1 active site inhibitors suppress cancer cell growth
We previously described TH5487 as a selective small
molecule inhibitor of OGG1 (39). To further understand
the precise function of this inhibitor, we here determined
the X-ray crystal structure of human OGG1 in complex
with TH5487 (Figure 3A), showing that it binds in the ac-
tive site, in an opposite orientation from the natural sub-
strate (39), with the iodophenyl tail of TH5487 occupying
the place of the 8-oxoguanine base. The OGG1 protein un-
dergoes a conformational change when binding DNA, into
a closed structural form. Here, we observe the benzimida-
zolone core interacts with a lipophilic exo-site outside the
active site, stabilized by Ile152 and Leu323 in addition to a
-stacking interaction with His270. Also, the carbonyl side
group of TH5487 makes a hydrogen bond with the Ile152
-amino backbone. Finally, the bromine atom of TH5487






















































































8 Nucleic Acids Research, 2020
Figure 1. OGG1 knockdown is selectively toxic in oncogene-expressing cells and cancer cell lines. (A) Viability of BJ fibroblast cells immortalized with
telomerase (BJ-Tert) or telomerase, SV40 large T protein and HRAS G12V oncogene (BJ-Ras) after OGG1 depletion for 5 days. Data are average ±SD
of 10 technical replicates representative of two independent experiments. (B) Clonogenic survival of BJ-Tert and BJ-Ras cells following OGG1 depletion.
Data are average±SD of 8–10 replicates from three independent experiments. (C) Representative immunoblot analysis of OGG1 expression in BJ-Tert and
BJ-Ras cells 48 h after transfection with siRNA. (D) Clonogenic survival of H460 cells stably transfected with doxycycline inducible shRNA constructs
targeting OGG1 (sh1–sh3) or a non-specific sequence (shNT). Cells were seeded in the presence or absence of 500 ng/ml doxycycline and colonies were
enumerated after 10–12 days. Data are average ±SD of six technical replicates from two independent experiments. All values are normalized to the number
of colonies in medium free of doxycycline. (E) Proliferation of A3 cells stably transfected with doxycycline-inducible shRNA constructs targeting OGG1
(sh2–3) or a non-specific sequence (NT). Cells were seeded in medium with or without 250 ng/ml doxycycline and counted daily. Cultures reaching a
density of more than one million cells per ml were added fresh medium to maintain cell growth and normalized to the starting density. (F) Representative
immunoblot analysis of OGG1 expression in H460 and A3 cells stably transfected with shRNA constructs targetingOGG1 and treated with doxycycline as
in D and E. Data are average ±SD of four technical replicates from two independent experiments. Statistical significance was determined using unpaired,
two-sided t-tests (**P< 0.01, ***P< 0.001 and ****P< 0.0001), in all cases comparing against the distribution of the corresponding non-specific RNAi-
sequence.


























































Figure 2. OGG1 knockdown reduces tumor growth in vivo. (A) A3 cells harbouring luciferase and a doxycycline-inducible shRNA construct targeting
OGG1 or a non-specific sequence were injected subcutaneously in mice. Doxycycline was added to the drinking water at day 7, and tumor growth were
monitored twice a week thereafter. Data are average ± SD, n = 8 per group. (B) Bioluminescence of luciferase expressing A3 cells in five representative
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Figure 3. The OGG1 inhibitor TH5487 is selectively toxic to oncogene-expressing cells and cancer cell lines. (A) Close-up view of ligand TH5487 (green)
binding to humanOGG1. Important residues in the binding site are marked, hydrogen bond interactions are shown in black dashed line, water (red sphere)-
mediated interactions in grey dashed line. (B) Comparison between the binding of ligand TH5487 (green) to human OGG1 (gray) with the structure of
TH5675 (pink) bound to mouse OGG1 (yellow, PDB 6G3Y). (C) Viability of BJ-Tert and BJ-Ras cells exposed to the indicated concentrations TH5487 for
five days. Data are average ±SD of four technical replicates from two independent experiments. (D) Clonogenic survival of cell lines exposed to TH5487.
The cancer cell lines ACHN and H460, and the non-transformed cell lines MRC5 and Ogg1−/− mouse embryonic fibroblasts (MEF) were incubated
for 6–11 days in the presence of the indicated concentrations TH5487, followed by colony enumeration. Data are average ±SD values of four technical
replicates, representative of three independent experiments. (E) TH5487 selectively decreases viability of cancer cell lines. EC50-values of 34 cancer (red)
and 7 non-transformed cell lines (blue). Cells were exposed to a dilution series of TH5487 for five days followed by a viability assessment using resazurin. All
cell lines were tested in two to ten independent experiments. Each point represents the EC50-value from one experiment (average of two or three technical
replicates). (F) Comparative analysis of EC50 values for TH5487 in cancer- and non-transformed cell lines, and CD34+ hematopoietic stem cells, CD34-
fraction from cord blood or PBMCs from healthy donor blood. All primary blood cells were tested upon activation with Dynabeads/Phytohemagglutinin
or not and exposed to a dilution series of TH5487 to calculate EC50 values by resazurin assay. Data for blood cells are average ±SD from two to four
independent donors, and are significantly different from the hematological cancer cell lines tested, using a two-sided unpaired t-test (*P < 0.05, **P <
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Ser326. This confirms the overall molecular mechanism of
this class of inhibitors (Figure 3B and Supplementary Fig-
ure S3), where OGG1 adopts a closed conformation upon
binding TH5487, thereby blocking OGG1 from accessing
substrate DNA lesions in DNA and chromatin (39).
To study if TH5487 selectively inhibited growth of
transformed cells, we incubated the pair of isogenic
BJ-fibroblasts with the inhibitor. TH5487 causes a
concentration-dependent decrease in viability in BJ-Ras
fibroblasts (Figure 3C), in line with reduced survival
after RNAi-mediated OGG1 downregulation (Figure 1A).
Furthermore, the isogenic hTERT-immortalized cells are
less sensitive to TH5487 than BJ-Ras (EC50 = 29.5 ± 4.7
M and EC50 = 11.4 ± 5.7 M, respectively, P < 0.05)
(Figure 3C), in line with high tolerance to OGG1 siRNA
(Figure 1A).We then characterized a subset of adherent cell
lines in colony formation assays and find TH5487 causes
a concentration-dependent loss of clonogenic potential
in the cancer cell lines ACHN and H460, whereas the
non-transformed cell lines MRC5 and Ogg1−/− mouse
embryonic fibroblasts were unaffected by treatment up to
20 M (Figure 3D). These results suggest that TH5487
may selectively kill cancer cells. To test this more broadly,
we determined the sensitivity of a large panel of cancer
and non-transformed cell lines and found overall that
TH5487 caused loss of viability in cancer cells while being
better tolerated in non-transformed cell lines (Figure 3E
and Supplementary Table S1). Moreover, this selectivity
was not unique to TH5487, since the TH5487 inhibitor
analogues TH5796 and TH6943 displayed a similar growth
inhibition specific to cancer cells (Supplementary Figure
S4A to S4F and Supplementary Table S1).
Finally, TH5487was well tolerated by a set of hematopoi-
etic primary cells derived from healthy donors (CD34+
cells, resting and activated CD34- cells from umbilical cord
blood (Figure 3F). Taken together, TH5487 caused loss of
proliferation to a higher degree in the tested cancer cell lines
(EC50 17.9 ±6.9 M) compared to non-transformed cell
lines (EC50 36.9 ± 7.5 M) (Figure 3F). Hematological
cancer cell lines were particularly sensitive compared to pri-
mary blood cells (EC50 14.7 ± 4.7 M and 35.1 ± 20 M,
P = 0.00029).
Anticancer properties overlap between OGG1 loss and
OGG1 inhibitors
We selected A3 cells as a model cell line to characterize
anti-proliferative properties mediated by either OGG1 in-
hibition by TH5487 or by shRNA knockdown of OGG1.
We found that similar to OGG1 knockdown (Figure 1E),
TH5487 inhibited proliferation of A3 and other T-cell acute
leukoblastic leukemia cell lines with an EC50 of ∼10 M
(Figure 4A and Supplementary Table S1). A3 cells exposed
to 10 MTH5487 showed slower proliferation for up to 72
h (Figure 4B), followed by a mild decrease in cell viability
(Figure 4C). The same dose of TH5487 was well tolerated
by resting and activated peripheral bloodmononuclear cells
(PBMCs) and primary T-cells from healthy donors (Supple-
mentary Figure S4G to S4K). Using Annexin V-propidium
iodide staining, we could demonstrate a slight but signifi-
cant increase in apoptosis after OGG1 knockdown and 5
and 10 M TH5487 treatment, which was more substan-
tial at 20 M (Figure 4D and E). To further characterize
the cell proliferation defect, we released the cells into fresh
medium after treatment. Similar to A3 OGG1 knockdown
cells, A3 cells exposed for 6 days to 10 M TH5487 were
able to divide normally after replacing with fresh cell cul-
ture media (Figure 4F to H) showing proliferation defects
due to OGG1 depletion or targeting with TH5487 to be re-
versible. This suggests that TH5487 might primarily cause
cytostatic rather than cytotoxic effects.
To test whether the antiproliferative effect of TH5487was
related toOGG1 inhibition,OGG1 knockdown cells treated
with doxycycline for 5 days were challenged for an addi-
tional 48 h with 10 M TH5487. However, no significant
additional toxic effect was detected (Figure 4I–K). Alter-
natively, A3 OGG1 shRNA cells were exposed to doxycy-
cline alone or in combination to TH5487 for 6 days and we
found that TH5487 had additional toxic effect for one of
the constructs (A3 sh2) but not for the other (A3 sh3) (Sup-
plementary Figure S5A and S5B). Interestingly, the combi-
nation of TH5487 and doxycycline in A3 sh2 knockdown
cells led to a partial recovery of OGG1 protein levels, which
might explain why TH5487 has an additional effect for this
specific construct (Supplementary Figure S5C and S5D).
Finally, to further investigate potential off-target effects of
the compound in an OGG1 knockout model, we evaluated
the clonogenic potential of HEK293T or HEK293T(KO)
cells exposed to TH5487 for a period of 8 days. Here, we
found that the colony area was significantly reduced in
the parental HEK293T OGG1 proficient cells compared
to HEK293T (KO) cells (Supplementary Figure S5E and
S5F). These results suggest that the antiproliferative proper-
ties of TH5487 in cancer cells are primarily related toOGG1
inhibition although residual off target effects at higher con-
centrations (20 M or more) cannot be excluded, since it is
a common mechanism of action of cancer drugs (58).
Targeting OGG1 results in replication stress
Given the general high levels of oncogene-inducedROS and
associated oxidative DNA damage in cancer (18–23), we
were curious if the loss of viability was preceded by ge-
nomic accumulation of oxidized DNA. To test this, we ex-
posed A3 cells to 10 M TH5487 for up to five days, puri-
fied genomic DNA, and measured the genomic content of
8-oxodG. Unexpectedly, 8-oxodG levels did not rise above
assay background levels during the experiment (Figure 5A).
Nor did 8-oxodG rise above background inOGG1-depleted
A3 cells (Supplementary Figure S6A). Using a more sensi-
tive method, we could detect genomic OGG1 substrates in
A3 cells using the modified Comet assay. Treatment with
10 MTH5487 caused a ∼50% increase in OGG1-induced
tail length, indicating that TH5487 induced a small increase
in OGG1 substrate levels in these cells (Figure 5B and C).
The overall increase in nuclear 8-oxodG in DNA is minor
in comparison to KBrO3 control and unlikely to explain
growth inhibition induced by OGG1 inhibitors or protein
loss.
In spite of few nuclear oxidative DNA lesions, we
found unexpectedly a significant increase in phosphorylated
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Figure 4. Anticancer properties overlap between OGG1 loss and OGG1 inhibitors. (A) Viability of T-cell acute leukoblastic leukemia cell lines treated
for 5 days with the indicated doses TH5487. Data are average ±SD of independent experiments (A3, n = 5; Jurkat, n = 3; MOLT-4, n = 4; CCRF-CEM,
n = 3). (B) Relative cell numbers and (C) viability (%) for A3 cells treated for 5 days with 10 M TH5487. Data are average ±SD of six replicates from
three independent experiments. (D) Induction of apoptosis in A3 cells treated for 72 h TH5487 and stained for Annexin V. Data are average ±SD of
three independent experiments. (E) A3 cells transfected with shRNA targeting OGG1 were treated with doxycycline for 6 days and stained for Annexin
V. Data are average ±SD of two independent experiments. (F) Scheme for recovery experiment in which A3 OGG1-shRNA cells or A3 cells were silenced
or inhibited for 6 days with doxycycline (200 nM) or TH5487 (10 M). Then, 250 000 cells/ml were seeded in fresh media and recovered for 24 h and
144 h by measuring cell number (G) and viability (H). Data are average ±SD of 2–6 technical replicates representative of two independent experiments
(I). Scheme for off-target effect evaluation in which A3 OGG1-shRNA cells were exposed to doxycycline for six days and after that, cells were exposed to
TH5487 (10 M) for 48 h followed by measurements of cell numbers (J) and viability by trypan blue exclusion (K). Data are average ±SD of two technical
replicates from four independent experiments. Statistical significance was determined using unpaired, two-sided t-tests (*P < 0.05, **P < 0.01, ***P <
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Figure 5. Effect of TH5487 on DNA lesions, DNA damage markers and DNA replication. (A) 8-oxodG accumulation in A3 cells. A3 cells were treated
with 20 mMKBrO3 for 1 h or with 10 MTH5487 for the indicated times, and the amount of genomic 8-oxodGwas quantified with LC-MS/MS.Data are
average ±SD of five replicates from two independent experiments. (B) Comet assay. A3 cells were treated with 10 MTH5487 for 72 h and strand-breaks
and OGG1 substrate lesions were analyzed with the OGG1-modified Comet assay. Representative images of cells are shown. (C) Violin blot of Comet
tail moment. Cells were treated as in B, and the tail moment of the cells were analyzed using blinded automatic analysis (n = 200 per condition from two
independent experiments). The full line indicates median, and the dotted lines quartiles. (D) Violin blot of phosphorylated H2AX intensity. A3 cells were
treated with 0.1% DMSO or 10 MTH5487 for the indicated times and stained for phosphorylated H2AX. Treatment with 2 mM Hydroxyurea for 1 h
was used as positive control. At least 33 000 nuclei per group were quantified from three independent experiments. The full line indicates median, and the
dotted lines quartiles. All values are normalized to that of the mean value of the 1 h non-treated sample. (E) Relative induction of positive H2AX cells
in OGG1 shRNA depleted cells for 72 h or OGG1 inhibited with 10 M of TH5487 for 24, 48 and 72 h. Data are average ±SD of two technical replicates
representative of 1–2 independent experiments (F) Relative cell cycle distribution of positive H2AX gated cells along G1, S or G2/M cell cycle phases
after 72 h treatment with 10 M TH5487. Data are average ±SD of two technical replicates from two independent experiments. (G) Experimental setup
of DNA fiber assay. A3 cells were treated with 0.1% DMSO or 10 MTH5487 for 48 h or 72 h, alternatively A3 shOGG#2 were treated with doxycycline
for 48 or 96 h followed by addition of 5-chloro-2′-deoxyuridine (CldU) or 5-iodo-2′-deoxyuridine (IdU) to the medium. Representative images of DNA
replication fibers are shown. (H) Distribution of fork speed in CldU-labelled A3 cells treated with DMSO or TH5487 for 48 or 72 h. (I) Total fork speed in
DMSO and TH5487-treated cells. (J) Distribution of fork speed in CldU-labelled A3 shOGG1#2 cells treated or not with doxycycline for 48 or 96 h. (K)
Total fork speed in A3 shOGG1#2 cells treated or not with doxycycline. Data shown as average ± SD from three independent experiments. At least 300
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as well as following shRNA depletion of OGG1 (Figure 5D
and E). Interestingly, the distribution of H2AX positive
cells after treatment by OGG1 inhibitors during cell cycle
revealed that the DNA damage induced by TH5487 was
confined to S-phase cells (Figure 5F), indicating that OGG1
deficiency may affect DNA replication. However, the A3
cell cycle distribution after OGG1 perturbation remained
largely constant, although we observed an accumulation
in the sub-G1 population (Supplementary Figure S6B and
S6C). Yet, OGG1 inhibition induced a marked reduction in
replication fork rate at both 48- and 72 h time points (Fig-
ure 5G to I), largely mimicked byOGG1 depletion by RNAi
at both 48- and 96-h time points (Figure 5G, J and K).
Furthermore, experiments where cells were pulsed with 5-
ethynyl-2′-deoxyuridine (EdU) followed by click-chemistry
mediated detection of newly incorporated nucleotides, sup-
ported that DNA synthesis was reduced in OGG1 inhib-
ited and OGG1-depleted cells (Supplementary Figure S7).
Together, these data demonstrate that the replicative poten-
tial of OGG1 perturbed cells may be caused by replication
stress in the form of a lowering of replication fork rate and
DNA damage during S-phase.
To explore how OGG1 inhibition causes replication
stress we performed RNA sequencing with A3 cells treated
with 10 M TH5487 or DMSO for 24 h. Gene Set En-
richment Analysis (GSEA) of the differentially expressed
genes revealed that ‘DNA replication’ was one of the most
downregulated gene signatures (Figure 6A and Supplemen-
tary Figure S8). Genes encoding key proteins and enzymes
necessary for DNA replication were downregulated upon
TH5487 treatment (Figure 6B and C). We validated a panel
of replication associated genes following OGG1 knock-
down, confirming a ∼50% downregulation after 96 h for
all eight investigated transcripts (Figure 6D). These results
suggest that TH5487 and OGG1 knockdown induce early
alterations in the A3 transcriptional profile that include
downregulation in DNA replication signature. These are
unlikely to be explained by a lack of replicating cells, since
cells in S-phase were not depleted from the cell population
in any experimental condition (Supplementary Figure S6B
and S6C).
Interestingly, the promoter sequence of several genes in-
cluded in the ‘DNA replication’ gene set contains one or
several SP1 transcription factor bindingmotifs (https://epd.
epfl.ch//index.php). Since OGG1 has been reported to be
required for recruitment of transcription factors such as
SP1 to the promoter of genes containing motifs of recog-
nition for this transcription factor (59), we exposed A3 cells
or OGG1-shRNA A3 cells to TH5487 for 72 h or doxycy-
cline for 96 h, respectively, and assessed promoter oxida-
tion at the SP1 binding motif contained within theMCM4
promoter. We observed a significant accumulation of ox-
idative DNA damage at this position that correlated with
a slight but significant downregulation of MCM4 mRNA
levels (Figure 6E and F).
Since our data indicated that OGG1 inhibitor treatment
slowed A3 cell proliferation, we wanted to test if treatment
with TH5487 could suppress growth of A3 xenograft tu-
mors in mice. We orally administered 20 mg/kg TH5487 in
established subcutaneous tumors of A3 cells. However, we
were not able to detect xenograft growth inhibition, even
after an increase in dose to 40 mg/kg after the first week
(Figure 7A). Since we were unable to demonstrate OGG1
target engagement in A3 cells in the derived xenograft tu-
mor (Figure 7B), we hypothesized that the lack of in vivo
TH5487 efficacy was due to lack of OGG1 target engage-
ment.
As TH5487 was shown to be stable in mouse serum (39),
we investigated if TH5487 interacted with serum proteins.
Thus, we incubated bovine serum albumin proteins together
with TH5487 and observed that bovine serum albumin in-
duced a marked loss of inhibition of OGG1 enzyme ac-
tivity (Figure 7C). This suggests that albumin competed
with OGG1 enzyme for TH5487 and severely reduced its
efficacy. Thus, we conclude that systemic administration of
TH5487 is not feasible with the current molecule and new
compounds or formulation strategies have to be developed
for effective treatment of cancer.
DISCUSSION
Despite the inherent high levels of ROS and DNA dam-
age in cancer, and the clinical success of BER pathway in-
hibitors, DNA repair pathways removing oxidative DNA
damage have so far not been pharmacologically targeted
(35). We and others (39,60,61) recently reported the first
examples of cell active inhibitors targeting OGG1, and
here we provide the first structural details of how TH5487
binds to the human enzyme (Figure 3A and B). Impor-
tantly, we show that multiple cancer cell lines are sensi-
tive to loss or inhibition of OGG1, which could relate to
an underlying addiction to a functional OGG1 in can-
cer. This may in part explain why Ogg1 knockout mice
are largely spared from cancer (62), and the relative rar-
ity of the expected C→A mutation signature in human
cancers (26) in spite of the well-demonstrated fundamen-
tal role of ROS in hyperplasias. Surprisingly, after treat-
ment with OGG1 inhibitor the absolute levels of genomic
8-oxodG remained low, at or above background levels
of one 8-oxodG per million guanines (corresponding to
about 3000 damaged bases per diploid genome), even af-
ter prolonged treatments with TH5487. This finding sug-
gests that a sizeable number of 8-oxodG in bulk chromoso-
mal DNA of cancer cells must be very low, even in stressed
cells. This may have broad implications for 8-oxodG as a
biomarker in cancer research since it questions the use-
fulness and applicability of indirect detection of genomic
8-oxodG in whole cells, using single-cell electrophoresis
and antibody- or avidin-staining. Instead, novel methods to
map and study specific genomic locations enriched with 8-
oxodG lesions have been developed. For example, mapping
of 8-oxodG in mouse embryonic fibroblasts (MEF) and
MCF10A breast epithelial cells, has revealed that 8-oxodG
is enriched at promoters and 5′ and 3′ untranslated regions
rather than randomly distributed (63–65). In MEF cells,
∼10 000 regions of 8-oxodG were enriched in WT mouse
embryonic fibroblasts compared to ∼18 000 regions when
Ogg1 was knocked out (63). Interestingly, 21 out of the
113 replication genes transcriptionally downregulated by
OGG1 inhibitors (ATG, CDK1, CDK2, CDK2AP1, DNA2,
E2F7, FEN1, MCM3, MCM4, NAP1L1, NFIC, NUCKS1,
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Figure 6. TH5487 treatment induces a downregulation of DNA replication genes (A) Gene Set Enrichment analysis plot of the DNA Replication Gene
Ontology Gene Set. A3 shNT cells were treated with 10 M TH5487 for 24 h or DMSO as control, and RNA sequencing was performed. Genes with a
mean normalized count > 5 were ranked by log2 fold change. Genes towards the top of the ranked gene list are upregulated after TH5487 treatment, genes
with higher ranks are downregulated. NES: normalized enrichment score, P value has been adjusted for multiple testing using the Benjamini–Hochberg
method. (B) Log2 fold changes in expression level of DNA Repair genes of TH5487 treated A3 control cells compared to DMSO treated cells. Only genes
with a mean normalized count >5 were analyzed. Visualization of the KEGGDNAReplication pathway. (C) Heatmap of the leading edge genes from the
DNA Replication Gene Ontology Gene Set. Genes and samples were unsupervisedly clustered using hierarchical clustering (euclidean distance, complete
linkage). Rows indicate technical replicates (n = 3). A negative z-score indicates relative downregulation, a positive relative upregulation of the gene. (D)
Relative mRNA expression levels of replication-associated genes in OGG1-depleted cells (normalized to A3 shNT and expressed in percentage). A3 shNT
or sh2-cells were treated with doxycycline for 72 h. Data shown as average ± SEM from four technical replicates from two independent experiments.
(E) Oxidation at MCM4 promoter. The indicated cells were treated with 10 M TH5487 or 250 ng/ml doxycycline for 72 and 96 h, respectively, DNA
was purified and treated or not with OGG1 followed by PCR amplification of the MCM4 promoter. Data shown are the difference in Ct values caused
by OGG1 enzymatic treatment or buffer. Data represent average ± SEM of three technical replicates from two independent experiments. (F) Relative
expression ofMCM4 mRNA levels in OGG1 perturbed cells expressed in percentage. Cells were treated as in D. and data represent average ± SEM 3–4
technical replicates from two independent experiments. Statistical significance was determined using a two-sided unpaired t-test (ns, non-significant, *P <
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Figure 7. OGG1 inhibitors does not inhibit tumor growth in vivo. (A) Lack of TH5487 efficacy in vivo. A3 cells were injected subcutaneously in mice,
allowed to graft for three days and then administered 20–40 mg/kg TH5487 orally, once a day on weekdays. Twelve days into the treatment, the dose was
increased to 40 mg/kg. Data are average± SD (n= 9 per treatment group). (B) TH5487 target engagement in A3 xenograft. Tumors were excised following
termination, and TH5487 target engagement was analyzed by cellular thermal shift assay, using an antibody specific for the human OGG1 protein. Data
are average ± SD (n = 4 different tumors per group). (C) Effect of bovine serum albumin on OGG1 inhibition by TH5487. A dilution series of TH5487
was incubated with OGG1 enzyme and a DNA reporter oligonucleotide containing an OGG1-substrate, in the presence or absence of 1% (w/v) bovine
serum albumin. Data are average ± SD of four technical replicates from two independent experiments.
SIN3A, SMC3), were included in the list of chromosomal
gene locations having 8-oxodG-enriched peaks inOgg1−/−-
MEF (63). This observation, together with our data show-
ing that OGG1 inhibition/depletion induces accumulation
of oxidative DNA damage at MCM4 gene promoter, and
downregulation of MCM4 mRNA levels, supports that
OGG1 might play a role in 8-oxodG epigenetic regulation
of gene expression. This adds to the growing list of obser-
vations where DNA oxidation in promoter sequences mod-
ulates gene transcription.
Indeed, our transcriptional study to evaluate the impact
of TH5487 in A3 cells revealed that differential gene ex-
pression are observed 24 h after OGG1 inhibition. OGG1
inhibition induced transcriptional downregulation of genes
involved in different biological processes such as cell cycle
control and DNA replication (Figure 6 and Supplemen-
tary Figure S8). This occurred earlier compared to some
of the replication stress phenotypes associated with OGG1
inhibition/downregulation observed in other assays. For ex-
ample, reduction in EdU incorporation was only detectable
after 96 h treatment with TH5487 or doxycycline in A3 cells
orOGG1-shRNAA3 cells respectively (Supplementary Fig-
ure S7). In addition, we have found reduced transcriptional
levels for all genes encoding for MCM2–7 complex after
TH5487 treatment (Figure 6) followed by a progressive ac-
cumulation of H2AX positive A3 cells during S-phase at
72 h (Figure 5). These results are not surprising considering
that MCM proteins are required for processive DNA repli-
cation and that loss of MCM function causes DNA dam-
age and genome instability (66,67). This suggests that tran-
scriptional downregulation ofDNA replication genesmight
be the earliest phenotype associated with TH5487 induced
replication stress in A3 cells.
Taking into consideration the selectivity of TH5487 for
arresting cancer cell proliferation (Figure 3), and that am-
plification and/or upregulationMCMsmembers have been
identified as biomarkers of progression and negative out-
come in several cancer types (68), including OGG1 in-
hibition in clinical prevention strategies for cancer treat-
ment, based on the MCMs expression status, could be
of benefit. On the other hand, the ready reversibility of
TH5487 in cell proliferation supports the cytostatic nature
of OGG1 inhibitors (Figure 4). Since cancer intervention
using cytostatic drugs alone is often ineffective, combina-
tion strategies using OGG1 inhibitors together with other
cancer-selective or cytotoxic drugs should be rationalized
and tested in preclinical cancer models to address the util-
ity of OGG1 inhibitors for cancer treatment. For that, sig-
nificant improvements to its formulation may be required
for the compound to show in vivo efficacy in longer term
experiments such as cancer xenograft studies. In particu-
lar, the affinity to albumin reported here, which cause more
than 99% of the molecule to associate with plasma pro-
teins (39) is a challenge that must be solved for TH5487
to be useful for in vivo applications where OGG1 must be
targeted over a long period of time to induce cell death
and inhibit proliferation. Alternatively, differences between
mouse strains, formulation or mode of administration may
account for the different outcomes of in vivo experiments
involving TH5487. Moreover, although TH5487 is well tol-
erated by mice (39), the possibility for off-target effects
at high doses (see e.g. Figure 4D) must be taken into
account.
In conclusion, we validate OGG1 as one more to the list
of existing BER factors, e.g., PARP1, as potential targets
for treatment of cancer.
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